Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Mariaserena Giliberto"'
Autor:
Pilar Ayuda-Durán, Johanne U. Hermansen, Mariaserena Giliberto, Yanping Yin, Robert Hanes, Sandra Gordon, Heikki Kuusanmäki, Andrea M. Brodersen, Aram N. Andersen, Kjetil Taskén, Krister Wennerberg, Jorrit M. Enserink, Sigrid S. Skånland
Publikováno v:
Cell Death Discovery, Vol 9, Iss 1, Pp 1-13 (2023)
Abstract The principle of drug sensitivity testing is to expose cancer cells to a library of different drugs and measure its effects on cell viability. Recent technological advances, continuous approval of targeted therapies, and improved cell cultur
Externí odkaz:
https://doaj.org/article/0b868ee39c1047a4b864764b20e6bee8
Autor:
Leonardo Miranda Santana, Deepak B. Thimiri Govinda Raj, Andrea Cremaschi, Mariaserena Giliberto, Alexandra Gade, Arnoldo Frigessi, Geir E. Tjønnfjord, Ludvig A. Munthe, Sigrid S. Skånland, Manuela Zucknick, Kjetil Taskén
Publikováno v:
HemaSphere, Vol 7, p e743599b (2023)
Externí odkaz:
https://doaj.org/article/fd7ad490e30e42b99eeb8b1340c8b413
Autor:
Katrine Melvold, Mariaserena Giliberto, Linda Karlsen, Pilar Ayuda‐Durán, Robert Hanes, Toril Holien, Jorrit Enserink, Jennifer R. Brown, Geir E. Tjønnfjord, Kjetil Taskén, Sigrid S. Skånland
Publikováno v:
Molecular Oncology, Vol 16, Iss 5, Pp 1153-1170 (2022)
Most patients with chronic lymphocytic leukemia (CLL) initially respond to targeted therapies, but eventually relapse and develop resistance. Novel treatment strategies are therefore needed to improve patient outcomes. Here, we performed direct drug
Externí odkaz:
https://doaj.org/article/67352beffad14b0ba011733748ab3689
Autor:
Mariaserena Giliberto, Deepak B. Thimiri Govinda Raj, Andrea Cremaschi, Sigrid S. Skånland, Alexandra Gade, Geir E. Tjønnfjord, Fredrik Schjesvold, Ludvig A. Munthe, Kjetil Taskén
Publikováno v:
Molecular Oncology, Vol 16, Iss 6, Pp 1241-1258 (2022)
The management of multiple myeloma (MM) is challenging: An assortment of available drug combinations adds complexity to treatment selection, and treatment resistance frequently develops. Given the heterogeneous nature of MM, personalized testing tool
Externí odkaz:
https://doaj.org/article/71633b5db14044a08b75a456ac66df48
Autor:
Mariaserena Giliberto, Leonardo Miranda Santana, Toril Holien, Kristine Misund, Sigve Nakken, Daniel Vodak, Eivind Hovig, Leonardo A. Meza-Zepeda, Eivind Coward, Anders Waage, Kjetil Taskén, Sigrid S. Skånland
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
IntroductionMultiple myeloma (MM) is a heterogeneous disease where cancer-driver mutations and aberrant signaling may lead to disease progression and drug resistance. Drug responses vary greatly, and there is an unmet need for biomarkers that can gui
Externí odkaz:
https://doaj.org/article/2b4da978d1fa40c8bdcb5d04f3de4053
Autor:
Muhammad Zahoor, Marita Westhrin, Kristin Roseth Aass, Siv Helen Moen, Kristine Misund, Katarzyna Maria Psonka-Antonczyk, Mariaserena Giliberto, Glenn Buene, Anders Sundan, Anders Waage, Anne-Marit Sponaas, Therese Standal
Publikováno v:
Blood Advances, Vol 1, Iss 27, Pp 2656-2666 (2017)
Abstract: Multiple myeloma (MM) is a hematologic cancer characterized by expansion of malignant plasma cells in the bone marrow. Most patients develop an osteolytic bone disease, largely caused by increased osteoclastogenesis. The myeloma bone marrow
Externí odkaz:
https://doaj.org/article/d8b05d66de814a69b4cc46a1e04fb50d
Autor:
Alvaro Köhn-Luque, Even Moa Myklebust, Dagim Shiferaw Tadele, Mariaserena Giliberto, Leonard Schmiester, Jasmine Noory, Elise Harivel, Polina Arsenteva, Shannon M. Mumenthaler, Fredrik Schjesvold, Kjetil Taskén, Jorrit M. Enserink, Kevin Leder, Arnoldo Frigessi, Jasmine Foo
Publikováno v:
Cell Rep Methods
Tumor heterogeneity is an important driver of treatment failure in cancer since therapies often select for drug-tolerant or drug-resistant cellular subpopulations that drive tumor growth and recurrence. Profiling the drug-response heterogeneity of tu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bba1caf517a73bfbba4251b417394a34
https://europepmc.org/articles/PMC10088094/
https://europepmc.org/articles/PMC10088094/
Autor:
Alvaro Köhn-Luque, Even Moa Myklebust, Dagim Shiferaw Tadele, Mariaserena Giliberto, Leonard Schmiester, Jasmine Noory, Elise Harivel, Polina Arsenteva, Shannon M. Mumenthaler, Fredrik Schjesvold, Kjetil Taskén, Jorrit M. Enserink, Kevin Leder, Arnoldo Frigessi, Jasmine Foo
SummaryTumor heterogeneity is an important driver of treatment failure in cancer since therapies often select for drug-tolerant or drug-resistant cellular subpopulations that drive tumor growth and recurrence. Profiling the drug-response heterogeneit
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::40b472a4b6e878168b0306612a6f62ad
https://doi.org/10.1101/2022.01.17.476604
https://doi.org/10.1101/2022.01.17.476604
Autor:
null Katrine Melvold, null Mariaserena Giliberto, null Linda Karlsen, null Pilar Ayuda‐Durán, null Robert Hanes, null Toril Holien, null Jorrit Enserink, null Jennifer R. Brown, null Geir E. Tjønnfjord, null Kjetil Taskén, null Sigrid S. Skånland
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4e0b2c80854590d5c5ef488afb15ccc0
https://doi.org/10.1002/1878-0261.13153/v2/response1
https://doi.org/10.1002/1878-0261.13153/v2/response1
Autor:
Katrine Melvold, Mariaserena Giliberto, Jorrit M. Enserink, Linda Karlsen, Sigrid S. Skånland, Jennifer R. Brown, Geir E. Tjønnfjord, Kjetil Taskén, Robert Hanes, Pilar Ayuda-Durán, Toril Holien
Publikováno v:
Molecular Oncology
Most patients with chronic lymphocytic leukemia (CLL) initially respond to targeted therapies, but eventually relapse and develop resistance. Novel treatment strategies are therefore needed to improve patient outcomes. Here, we performed direct drug
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d4643c552e9397d1872ff5349286a680
http://hdl.handle.net/10852/91053
http://hdl.handle.net/10852/91053